SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing ...

in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), has been accepted as a late-breaking poster presentation at the European Association for the Study of the Liver ...

Poster applications for the 2025 Office of Interdisciplinary Graduate Program's (OIGP) Spring Reception are now closed. Our reception will take place in-person this year on May 7th, 2025 from 9:30 a.m ...

Zentalis Pharmaceuticals, Inc. announced that an abstract has been accepted for a poster presentation at the 2025 American Society of Clinical Oncology Annual Meeting, scheduled for May 30 to June ...

See also the URCC Symposium pages on the Symposium online platform, Abstract writing, and Presentation tips for your oral presentation. Make a 48" x 36" poster for the URCC Symposium. Posters this ...

For more and to view the abstract, visit the AACR Annual Meeting website. As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink ...

today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson’s disease will be presented at the AD/PD™ 2025 International Conference on Alzheime ...

Poster presentation to highlight new data on MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting. Agendia to present at Breast Fellows University ...